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PREVALENCE OF ALCOHOL AND DRUGS IN NEW YORK CITY DRIVERS 
 
ANI KAZARYAN 
 
ABSTRACT 
Purpose: The purpose of this study was to investigate the potential relationship 
between alcohol and drug prevalence in drunk- and drug-impaired driving cases in New 
York City (NYC) between January 1, 2015 and December 31, 2017 and to determine how 
this prevalence has changed over time.  The study also investigated the demographic 
characteristics of drivers to determine if there are certain groups who are consistently 
involved in alcohol and/or drug abuse while operating a motor vehicle.   
Methods: This retrospective study determined the alcohol and drug prevalence in 
individual drivers represented as cases per year over three consecutive years.  A total of 
613 cases were included in the study for individuals, age 16 to 75 years old arrested for 
suspicion of driving while intoxicated (DWI) in NYC.  Individual data collected included 
basic demographic information, time and day of incident, borough in which incident 
occurred, type of matrix used for toxicological analysis and the presence and absence of 
alcohol and/or drugs.  Drug findings were combined into classes based on their likely 
effect and included the following categories:  alcohol, antidepressants, cannabinoids, 
narcotic analgesics, sedatives, stimulants and other. 
Results: Results from the study compared data over three consecutive years from 
DWI cases (2015 to 2017).  In comparing prevalence of drug classes by year, the percent 
of cases tested positive for cannabinoids, narcotic analgesics and stimulants changed 
significantly from 2015 to 2017.  Delta-9-tetrahydrocannabinol (THC), the active 
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component of marijuana, was the most frequent individual drug identified using a 
screening method.  The prevalence rate of cannabinoids increased significantly in 2017 to 
43.0% from 32.5% the previous year and 29.3% in 2015.  The narcotic analgesics 
prevalence rate increased significantly in 2016 to 28.5% from 13.4% in the previous year 
and slightly decreased to 26.9% in 2017.  Comparison of stimulants by year showed a 
significant increase in 2017, 28.1% versus 19.0% (2016) versus 18.3% (2015).  When 
comparing the 2017 results to the drugs tested for in 2015 and 2016, significantly higher 
daytime drug prevalence was found between the previous years and 2017.  In evaluating 
race and drug use, white drivers were significantly more likely to test positive for 
sedatives and stimulants than other races.  In Manhattan, there was a significantly higher 
alcohol detection rate compared to the other boroughs and in Staten Island there was a 
significantly higher narcotic analgesics detection rate.  In comparing the top five 
individual drugs identified by borough, cannabinoids were the most common drug across 
all of the boroughs.  Alprazolam and cocaine (identified by its metabolite, 
benzoylecgonine, 98% of the time) were the next most frequently encountered drugs 
alternating as the top two and three drugs identified in the following four boroughs:  
Manhattan, Queens, the Bronx, and Staten Island.  Phencyclidine (PCP) (“angel dust”) 
was identified in the top five for Manhattan, the Bronx and Staten Island.  A statistically 
significant negative association was found between cannabinoid-positive and alcohol-
positive drivers.  The percentage of drivers with a BAC greater than .08 g/dL was 
significantly lower among cannabinoid-positive drivers than those who tested negative 
for cannabinoids.  Although there were no strong correlations between drug classes, 
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sedatives were associated (according to significant correlations) most to other drugs 
(correlated to 6 out of 6 categories).      
Conclusions: This study summarizes the results of the first OCME FTL of NYC 
toxicological findings in DWI cases to estimate alcohol and drug-involved driving 
prevalence.  It is important to note that this is a prevalence study and not a study that 
reports the risks associated with drugged-driving.  Since many drugs may be detected 
long after its impairing effects are gone, the focus of this study was to merely convey the 
use of particular drugs in the driving population.  
ix 
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1. INTRODUCTION 
 While alcohol-impaired driving has been studied and researched since the mid-
1900s, drug-impaired driving in the United States (US) is still a relatively new topic of 
research in roadside crash and safety.  For the first time in 2007, the U.S. National 
Roadside Survey (NRS) conducted a research study that obtained drug data beyond 
alcohol from different biological matrices [1].  The prevalence estimates for drug-
involved driving from the 2007 NRS provided a first look at the Nation’s drug use in 
relation to roadside traffic and safety.  With the establishment of the National Highway 
Traffic Safety Administration (NHTSA) in 1968 and further creation of the Fatality 
Analysis Reporting System (FARS) in 1975, States customarily perform alcohol analysis 
and measure blood alcohol concentration (BAC) for all fatality injured drivers and 
pedestrians.  The Grand Rapids Study in 1964 facilitated in creating a measurable 
relationship between breath alcohol concentration (BrAC) and crash risk, associating 
approximately 0.04 g/dL with an increased crash risk for drivers [2].  Crash risk grew 
exponentially with any concentration above the aforementioned minimum level.  
Although the analysis of drugs in addition to alcohol is not routinely tested for by the 
States, psychoactive drugs may influence the risk of road traffic crashes as it pertains to 
the dose taken, the time between using the drug and driving, frequency of drug use, and 
whether the drug is being used medicinally or illicitly [3].  The prevalence of such drugs 
and their risk factors would provide sensible feedback to toxicology laboratories and 
public policy efforts in reducing driving while intoxicated (DWI) cases.   
This study was conducted to investigate the potential relationship between alcohol 
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and drug prevalence in drunk- and drugged- driving cases in New York City (NYC) 
between January 1, 2015 and December 31, 2017 and to determine how this prevalence 
has changed overtime. The data obtained for this study consisted of drivers involved in 
traffic accidents or those pulled over by law enforcement within NYC’s five boroughs 
(Manhattan, Bronx, Brooklyn, Queens and Staten Island).  Data included drug test results 
obtained from blood, serum and urine samples provided by the drivers and submitted to 
the Office of Chief Medical Examiner (OCME) Forensic Toxicology Laboratory (FTL) 
of NYC.  The drugs studied included 116 over-the-counter, prescription, and illegal 
substances.  Results also included blood alcohol concentration or its whole blood 
equivalent (per NY state laboratory regulations) to enable comparison and provide results 
of combined alcohol and drug use.  The data was fundamental in providing accurate 
assessments of the presence of alcohol and other drugs in drivers and for evaluating the 
prevalence of alcohol and drug use in driving while intoxicated (DWI)/driving while 
ability impaired (DWAI) cases.       
 
1.1 Background 
With over one hundred years of research, alcohol and drunk driving has been 
evidenced to be the main causes of road traffic crashes [4].  Nonetheless, driving under 
the influence of drugs whether prescribed or illicit are also linked to increased risk of 
being involved in a road traffic incident [5-7].  The OCME FTL performs analyses on a 
limited number of cases submitted by law enforcement agencies with the purpose of 
determining the presence or absence of alcohol and other drugs and to evaluate their role 
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in modifying human performance or behavior as related to operation of motor vehicles.  
The FTL performs human performance forensic toxicology (HPFT) testing on specimens 
submitted by the New York City Police Department (NYPD), District Attorney’s Office 
or other legitimate law enforcement agencies [8]. 
 
1.2 Public Health Concerns & Possible Solutions 
Although studies have shown negative associations between drug use and driving 
impairment, driving under the influence of drugs is still a large area of research that 
requires continued assessment.  In 1981, the New York State (NYS) Legislature created 
the Special Traffic Options Program for Driving While Impaired (STOP-DWI) to 
encourage DWI prevention and reduce alcohol and drug-related road traffic injuries or 
fatalities [9].  While the program was the first of its kind in the Nation, efforts to bring 
more awareness to drugged-driving and its destructive force when combined with alcohol 
requires more attention.  In 2014, NYC implemented the Vision Zero program focusing 
on zero tolerance for traffic fatalities.  The Vision Zero Action Plan released initiatives 
that would lower serious injury and death rates in the streets of NYC.  Since there has 
been rigorous campaigning over the years to avoid drunk-driving accidents and ensure 
wearing seatbelts, Vision Zero further expands on street safety.  Several of the program’s 
initiatives currently in progress include examining pedestrian fatality locations and 
identifying intersections that may require new traffic signals [10].  Nonetheless, data 
analysis to proactively identify the presence of prescription or illicit drugs among drivers 
driving while ability impaired is also critical to street safety.  The grave nature of 
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drugged-driving remains problematic and demands awareness.   
The systematic analysis of drug data from DWI cases allows the NYC OCME 
FTL to understand the city’s illicit drug use as it pertains to alcohol- and drugged-driving.  
The direct proportion of blood alcohol concentrations to driving impairment in drunk 
drivers is not readily met the same way in drugged drivers.  The specific levels of 
impairment in drugged drivers cannot be easily determined for drug concentrations.  
Drug metabolism becomes more complicated as drugged drivers present polydrug use, 
commonly in combination with alcohol or other drugs.  The presence of drugs and its 
effect on driving is too complex to reckon as impairment across all individuals since 
people may react differently to the same drug(s) and tolerance develops with chronic 
users.  Reducing drug-involved/impaired driving has been and continues to be a national 
policy concern.  This study serves as a resource for supporting drug enforcement 
initiatives in NYC as it identifies information on the prevalence and types of drugs in 
addition to emerging drug problems.   
 
1.3 Rationale for Study 
 Due to the importance of the opioid epidemic and prevalence of marijuana usage, 
such possible serious public health consequences are crucial for investigation. 
Controversial issues such as the legalization of recreational use of marijuana in NYS 
would benefit from results obtained in this study.  The study aimed to determine the 
prevalence of marijuana and other drugs identified in the drivers as a proportion of the 
presence of delta-9-tetrahydrocannabinol (THC) or other metabolites versus the 
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proportion of cases submitted to the FTL.  The demographic characteristics of the 
individuals in addition to time of incidence and borough within which the incident 
occurred were all evaluated in the study.  These factors were used to help determine if 
certain sub-populations were more in danger of falling victim to using and driving under 
impaired conditions. Furthermore, the results of this study can be used as a reference in 
further studies evaluating trends and changes over time.     
 
1.4 Thesis Questions 
1. What is the relationship between alcohol consumption and cannabinoid use over 
time (alone and in combination) as it relates to incidence of DWI? 
2. What is the relationship between the use of drugs and the incidence of DWI 
overtime? 
3. What is the relationship between the demographic profile of drivers, location 
(borough), time of day and day of week as it pertains to the prevalence of alcohol 
and/or drugs? 
4. Can a strong correlation be observed between the drug classes? 
5. What is the association between the drug classes and the independent variables 
such as gender, age, race, etc.?  
6. Do gender, age, race and location (borough) highly influence the alcohol/drug use 
behavior of the drivers? 
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2. METHODS 
2.1 Study Design 
 This retrospective study was designed to determine the relationship between the 
prevalence of alcohol and drugs and the incidence of DWI among a sample of NYC 
drivers.  All data was obtained from the OCME FTL of NYC.  Within the time frame the 
data for this study was collected, the OCME FTL received only the NYPD DWI cases 
suspected of drugged-driving.  The NYPD Liaison Unit would filter the DWI cases 
suspected of alcohol only to the NYPD Police Laboratory and the drug related cases to 
the OCME FTL, resulting in a small portion of, not only the DWI suspected drivers in 
NYC, but of the 3.8 million drivers on NYC’s roads [11].       
DWI cases were chosen based on being filed under road traffic cases in the FTL.  
Each case was treated as one individual in the study.  The study population included men 
and women whose specimens had been submitted to the FTL for toxicological analysis 
arrested for suspicion of driving while under the influence of alcohol or drugs in NYC 
(total 5 boroughs) from January 1, 2015 to December 31, 2017. The exclusion criterion in 
the study sample was applied to excluding individuals from the study that did not have an 
adequate amount of specimen volume for toxicological analysis.  Information regarding 
vehicle type was also collected in the study; however, due to inconsistent reporting of 
vehicle type it was excluded from the study.  Drivers with unrecorded age, gender or 
borough were also excluded from the analysis.    
 The following data was collected from an individual’s case file:  age, race, 
toxicological analysis findings, time and day incidence occurred, and borough in which 
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incident occurred.  White Hispanic and African American Hispanic individuals were both 
grouped under Hispanic.  New York City includes the following five boroughs:  Bronx, 
Kings (Brooklyn), New York (Manhattan), Queens and Richmond (Staten Island).  
  
2.2 Analytical Testing Guidelines 
 The FTL uses the same analytical methodologies applied to post mortem testing 
to HPFT testing. Blood, serum and urine samples were subjected to laboratory screening 
via enzyme-linked immunosorbent assay (ELISA, Dynex Technologies Inc., Chantilly, 
VA, USA) micro-plate technology, followed by a confirmatory analysis by gas 
chromatography/mass spectroscopy (GC/MS, Agilent Technologies, Santa Clara, CA, 
USA), liquid chromatography/mass spectroscopy (LC/MS, Agilent Technologies, Santa 
Clara, CA, USA) or liquid chromatography/mass spectroscopy-mass spectroscopy 
(LC/MS-MS, Agilent Technologies, Santa Clara, CA, USA).  The initial testing 
(screening) depends on the type and amount of specimens submitted to the FTL. 
If blood and urine were available, blood was tested for the presence of volatiles 
such as ethanol, resulting in a blood alcohol concentration (BAC), isopropanol and 
acetone by head-space gas chromatography (HS/GC, Agilent Technologies, Santa Clara, 
CA, USA).  This study excluded findings of isopropanol and acetone since acetone is not 
only the major metabolite of isopropanol, which is not a major component in DWI cases, 
but also can be present and metabolized during diabetic ketoacidosis (a health condition).  
The study also excluded caffeine, cotinine (nicotine metabolite) and nicotine from the 
rate of drug prevalence measured.  These substances are not typically associated with 
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driving impairment and therefore not found relevant for our study purposes.     
If BAC was measured in both blood and urine specimens, for the purposes of this 
study, only the blood BAC measure was used since urine is not an accurate representation 
of the level of alcohol in the brain at the time of collection, whereas a blood alcohol level 
is.  Results in urine represent significantly higher or lower levels than actual BAC levels.  
Eight cases in 2017 only had urine specimen submitted, so whole blood equivalent values 
were used in the study for comparison purposes.   
 If blood and urine were available, screening methods were performed on the 
blood: ELISA to test for the presence of amphetamines, cannabinoids, barbiturates, 
opiates, benzoylecgonine, benzodiazepines, oxycodone and methadone, and a GC/MS 
analysis for basic drugs.  Fentanyl was added to the ELISA screening panel in mid-2016.  
The same procedure was applied to urine if blood was not submitted, however, 
oxycodone and methadone were excluded from the panel.  Positive results from screening 
tests were confirmed in the same matrix they were screened, and more importantly, 
quantitative results were always preferred from blood.  For the purposes of the study, if a 
driver tested positive for one or more of the drugs either in the blood, serum and/or urine 
analysis, the result was considered as one positive-detection for that drug finding.   
 The FTL selects drugs for analysis based on the HPFT standards in the field.  This 
includes drugs that might have impairing effects while driving and their probability of 
emerging in drivers.  Parent drugs and its metabolites were also consolidated and 
considered as one positive-detection and grouped under the parent drug.  For example, 
methamphetamine and amphetamine were combined since 1) amphetamine is a 
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metabolite of methamphetamine and 2) they have similar effects [12].        
Since the toxicological results revealed a large number of drugs in this data, the 
drugs were combined into classes based on their likely effects.  Drug classes included 
antidepressants, cannabinoids, narcotic analgesics, sedatives, stimulants and other.  Drug 
classes (Table 1) group drugs by the way they are used to treat a medical condition or by 
their active ingredient.  For example, the narcotic analgesics class contains opioids that 
are used to treat pain by affecting the central nervous system (CNS) and pain receptors in 
the brain.  In this study, there were 116 drugs and metabolites grouped into the various 
classes.  Changes in drug testing methods over time allowed significantly lower detection 
thresholds for a number of drugs in 2016 and 2017 relative to 2015 and 2016 as noted by 
“drugs not identified in 2015/2016” in Table 1. 
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Table 1.  Drug Class Composition.
 
Metabolites, analogs, intermediates are listed in italics.   
* Drugs not identified in 2015.  § Inactive metabolites not included in data analysis. 
† Drugs not identified in 2016. (( Indicate drugs identified through urine analysis only and are impurities from cocaine  
‡ Drugs that can be either a metabolite or a drug on their own. synthesis not included in data analysis.  
able 1.  Drug Class Composition. 
Antidepressants Narcotic Analgesics Sedatives Stimulants Other 
SSRIs and SNRIs 
Citalopram 
Sertraline 
Venlafaxine† 
 
Tricyclics 
Doxepin† 
 
Tetracyclics 
Mirtazapine† 
Trazodone† 
 
Miscellaneous 
Bupropion† 
Buproprion Erythro-Amino† 
Buproprion Morphinolol† 
Buproprion Threo-Amino† 
 
Methadone 
EDDP*§ 
Methadone 
 
Opiates 
6-MAM 
Acetylcodeine* 
Codeine‡ 
Heroin† 
Morphine‡ 
Norcodeine† 
 
Opioids 
Hydrocodone‡ 
Hydromorphone‡ 
N-desmethyltramadol†§ 
Noroxycodone† 
Oxycodone 
Oxymorphone‡ 
Tramadol† 
 
Synthetic Opioids* 
4-ANPP* 
Acetyl fentanyl† 
Acryl fentanyl† 
Fentanyl 
Fluoroisobutyrylfentanyl† 
Furanyl fentanyl* 
Isobutyrl fentanyl† 
Norfentanyl†§ 
U-47700* 
Barbiturates 
Butalbital 
Phenobarbital* 
 
Benzodiazepines 
Alprazolam 
Alpha-hydroxyalprazolam 
Clonazepam 
7-aminoclonazepam 
Chlordiazepoxide* 
Diazepam‡ 
Etilozam* 
Lorazepam 
Midazolam 
Nordiazepam‡ 
Oxazepam‡ 
Temazepam‡ 
 
Anesthetics 
Etomidate 
Lidocaine 
Pramoxine 
Procaine 
 
Muscle Relaxants 
Cyclobenzaprine† 
 
Hypnotics 
Zolpidem 
Amphetamines 
Amphetamine‡ 
Ethylone 
MDA*‡ 
MDMA* 
Methamphetamine 
 
Cocaine 
Cocaine 
Benzoylecgonine 
Cinnamoylcocaine(( 
Ecgonine Methyl Ester 
Ethylbenzoylecgonine 
Norcocaine§ 
Trimethoxycocaine(( 
 
Synthetic Cathinones 
Bath Salts 
 
Substituted Cathinones 
N-Ethylpentylone† 
N,N-dimethylpentylone† 
Pentylone* 
 
Miscellaneous 
Caffeine 
Cotinine 
Nicotine 
Analgesics 
Acetaminophen 
Acetyl-aminoantipyrine* 
Ibuprofen† 
Naproxen† 
Salicylate 
 
Anticonvulsants 
10-OH-Carbazepine 
Carbamazepine 
Gabapentin† 
Iminostilbene 
Levetiracetam 
Oxcarbazepine 
Phenytoin 
Lamotrigine† 
 
Antifungals 
Fluconazole 
Terbinafine† 
Antihistamines 
Cetirizine§ 
Cycroheptadine† 
Desloratadine† 
Diphenhydramine 
Doxylamine 
Norchlorcyclizine†§ 
Nordiphenhydramine 
Norhydroxyzine† 
Promethazine† 
Antiarrhythmics 
Diltiazem† 
Quinine and/or Quinidine† 
 
Antipsychotics 
Quetiapine† 
 
Antivirals 
Amantadine 
 
Cough Suppressants 
Dextromethorphan 
Guaifenesin† 
 
Hallucinogens† 
 
Depressants 
Gamma-hydroxybutyric acid† 
 
Dissociative Anesthetics 
Ketamine  
Norketamine‡ 
PCP 
 
Synthetic Cannbinoids 
AB-CHMINACA 
 
Miscellaneous 
Ephedrine† 
Levamisole 
Metoprolol† 
Phenylpropanolamine† 
Theophylline 
Trimethoprim† 
Cannabinoids 
Marijuana 
THC 
11-OH-THC† 
THC-COOH§ 
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2.3 Outcome Measures  
 The primary outcome measure of this study was the relationship between the 
prevalence of alcohol and drugs and the incidence of driving while impaired as seen in 
Figure 1.  
 
Primary Outcome Measure 
 
 
 
Figure 1.  Primary Outcome Measures. 
 
The secondary outcome measure was to determine if certain sub-populations were 
more or less likely to test positive for alcohol and/or drugs in the DWI cases (Figure 2). 
 
 
 
Figure 2.  Secondary Outcome Measures. 
 
 The data that were collected to determine primary and secondary endpoints for 
this investigation was detailed above.   
 
Incidence of DWI 
 
Proportion of drivers who 
tested positive for the 
presence of alcohol and/or 
drugs 
 
Is a certain sub-population of drivers more or less likely to test positive for alcohol 
and/or drugs? 
Day of 
Week Gender Age Race 
Time of 
Day Borough 
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2.4 Statistical Analysis 
The study examined the toxicological findings of drivers including driver 
characteristics (age, sex, race, drug-positive and BAC), DWI circumstances (day of the 
week, time of day and year) as well as location (borough) of incident.  Race/ethnicity was 
grouped as White, African American, Asian/Pacific Islander, Hispanic (include White 
and African American Hispanic) and unknown (excluded from the study).  BAC was 
measured in grams per deciliter.  Time of incident was grouped as daytime (occurring 
between 8:00 a.m. and 5:59pm) and nighttime (occurring between 6:00pm and 7:59 
a.m.).  
Drug classes were used to present the prevalence of drugs in the study.  Pearson’s 
chi-squared test (χ2) with an alpha level of 0.05 applied to the categorical data to 
determine whether drivers positive or negative for alcohol and drug use differed by driver 
characteristics and DWI incidence.  The Independent Samples t-Test was used to 
compare whether the mean age difference between drug classes were significant.  Models 
were created using binary logistic regression (LR) for all drug classes except 
antidepressants, which were encountered infrequently among the drivers in the study.  
Drivers with a .08 g/dL BAC or greater were considered to be alcohol-positive in the 
correlation study.  Whereas drivers with a .01 g/dL BAC or greater were considered to be 
alcohol-positive in the logistic regression study.  Data analyses were performed using 
IBM SPSS software (Armonk, NY, USA).                
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2.5 Description of Drug Classes 
There are many difficult elements in identifying drug-impaired drivers since 
different drugs not only have distinguishable effects on driving-related abilities, but also 
vary based on the individual’s response and reaction to the drug being consumed [13].  
 
2.5.1 Alcohol 
Alcohol is a drug that mainly affects the CNS and first becomes evident in areas 
of the brain involved in dealing with complicated tasks like skilled performance.  The 
effects of alcohol and driver performance have been studied for the past century and have 
been known to show that substantial impairment occurs at very low BACs.  Alcohol 
induced impairment may affect short-term memory, interpreting sensory information and 
regulatory movement repetitions.  According to a study on the effects of alcohol and 
other drugs on driver performance, “all individuals are impaired at any level of alcohol 
and the impairment increases as the BAC increases” [14].      
 
2.5.2 Antidepressants 
 The class of antidepressants is comprised of selective serotonin reuptake 
inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclics, 
tetracyclics and other compounds that are chemically unrelated to the aforementioned 
antidepressant classes.  Potential side effects of antidepressants include cognitive 
impairment, especially if present in higher doses or if used beyond its medical need or 
therapeutic treatment.  These drugs, coupled with alcohol may also further cause a 
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possibility of impairment [15].  Use of tricyclic and tetracyclic antidepressants may 
trigger drowsiness or sedation and thus impair psychomotor abilities.  The sedating effect 
of antidepressants is greatest when the dose is increased [16].  While the tricyclic 
antidepressants can be relatively impairing, SSRI antidepressants affect driving abilities 
less in comparison and do not really interact with alcohol [17].     
  
2.5.3 Cannabinoids 
 Marijuana is the common name given to the leaves of the plant cannabis sativa.  
This plant consists of 483 known compounds and at least 85 other cannabinoids, which 
have its effects on cannabinoid receptors in cells and act by suppressing the release of 
neurotransmitter in the brain.  For this study, the cannabinoids class is comprised of the 
psychoactive substance found in marijuana, delta-9 tetrahydrocannabinol (THC).  
Marijuana was only analyzed via a preliminary cannabinoids ELISA screen at the FTL.  
While marijuana also contains two other metabolites, its active metabolite, 11-hydroxy-
delta-9-tetrahydrocannabinol (“hydroxy-THC”, noted as 11-OH-THC) and its inactive 
metabolite, 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (“carboxy-THC”, noted as 
THC-COOH), marijuana confirmation analysis is not performed in-house at the FTL and 
requests for further confirmation and quantification are outsourced to another laboratory.  
For the purposes of this study, the cannabinoid prevalence rate is based solely on ELISA 
screening.      
 Cannabinoids are known to have many effects on humans and are noted for their 
sedative, stimulant, and hallucinogenic effects.  Studies vary on the effects of THC, 
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however, some findings demonstrate that when THC is found coupled with alcohol in 
drivers, this pairing leads to greater impairing effects than what is found with alcohol 
alone [18].  The greatest impairment is observed after one hour of smoking, at which time 
THC levels are 5-10% of the peak concentration [19].  Due to the long metabolic half-life 
of cannabinoids, drug-positive results may indicate the consumption of marijuana within 
a month and cannot necessarily be used as an accurate estimation of when it was 
smoked/consumed or at what concentration.     
 
2.5.4 Narcotic Analgesics 
 Narcotic analgesics include methadone and opioids.  Methadone, which has 
EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) as its primary inactive 
metabolite, is used medically for pain relief and long-term maintenance therapy for opiate 
addicts. Opioids are narcotic analgesics, which have its effects on the opioid receptors in 
the brain, spinal cord, and digestive tract. Primarily utilized as pain medications, 
oxycodone and hydrocodone fall into this class of drugs. Opioids are CNS depressants 
and when paired with other CNS depressants e.g. alcohol and sedatives, decreased 
performance. Opiates are derived from the poppy plant and include 6-
monoacetylmorphine (6-MAM, an active metabolite of heroin, which further breaks 
down to morphine), codeine, and morphine. Morphine as observed, can either be a 
metabolite or a drug on its own.  Out of these opiates, 6-MAM is indicative of recent 
heroin use, which is an illegal substance.  Synthetic opioids such as fentanyl, while often 
used in intensive medicine and may represent administration after traffic accidents, were 
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nonetheless included in the study as it’s being identified frequently in roadside cases.   
 
2.5.5 Sedatives 
 The class of sedatives includes anesthetics, barbiturates, benzodiazepines, 
hypnotics, and muscle relaxants.  Anesthetics are widely used to prevent pain during 
surgery, but certain local anesthetics such as lidocaine and procaine may be used as 
adulterants in cocaine and therefore, observed in this study as cutting agents.  
Barbiturates are commonly prescribed CNS depressants, particularly for migraine pain 
and anti-epilepsy, and are linked to delayed reaction times and loss of concentration, 
which may thus impair driving abilities [20].  Benzodiazepines are utilized for its 
effectiveness in reducing anxiety, help with sleep-related disorders, and prevention of 
seizures.  Alprazolam (Xanax), Lorazepam (Ativan), Clonazepam (Klonopin), Diazepam 
(Valium) and Temazepam (Restoril) are the five most prescribed and most frequently 
encountered benzodiazepines on the illicit market [21].  These CNS depressants can 
potentiate the effects of alcohol, and have been linked to impaired driving [8]. Thus, 
despite its therapeutic effect of sedation, benzodiazepines may notably have destructive 
effects on driving. Hypnotics, which are sleep-inducing drugs, such as zolpidem 
(Ambien), may cause drowsiness and dizziness.  These side effects may be increased and 
enhanced when the drug is taken with alcohol and can have destructive effects on driving 
[22].  Muscle relaxants, such as cyclobenzaprine (Flexeril), may also cause dizziness or 
drowsiness.  These side effects have been associated with weaving and striking parked 
cars and other still items [23].     
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2.5.6 Stimulants 
 As CNS stimulants, medical uses of this drug class contain treatments for weight 
loss, daytime drowsiness (narcolepsy), and attention deficit hyperactivity disorder 
(ADHD).  While stimulants can be used medically, they are commonly used and abused 
illegally.  Illegal stimulants observed in this study consist of the following: amphetamine, 
methamphetamine, 3,4-Methylenedioxyamphetamine (MDA), 3,4-
Methylenedioxymethamphetamine (MDMA) and cocaine.  Amphetamines have been 
linked to car crashes and may impair driving during stimulus and withdrawal phases.  
The withdrawal stage in particular is connected to fatigue, thus leading to harmful driving 
conditions [24].  MDMA, commonly known as ecstasy, is also known to produce 
hallucinogenic effects.  Low doses of stimulants have shown to enhance attention and 
cognitive performance [25-26].  However, a higher dose linked to leisurely use has been 
known to show the following effects: speeding, aggressive behavior, distracted driving 
and off-road collisions.  The effects of cocaine deteriorate rapidly and further cause 
exhaustion, drowsiness, and distraction in the withdrawal stage [27].   
 
2.5.7 Other Drugs 
 Other drugs include other analgesics, anticonvulsants, antifungals, antihistamines, 
antiarrhythmics, antipsychotics, antivirals, cough suppressants, other depressants, 
ketamine, phencyclidine (PCP), synthetic cannabinoids and drugs grouped as 
miscellaneous.  Anticonvulsants are commonly known as anti-seizure drugs and are used 
in treating epileptic seizures.  Antihistamines block histamine release from histamine-1 
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receptors and are commonly used to treat allergies or cold and flu symptoms. They can 
also have depressive CNS effects [28].  Several of the antihistamines observed in this 
study were cetirizine, diphenhydramine, doxylamine and promethazine.  Cough 
suppressants such as dextromethorphan, which is a CNS depressant and synthetic analog 
of codeine, can impair driving [29].  Dissociative anesthetics such as ketamine and PCP 
are recreationally used and known to have psychedelic and hallucinogenic effects.  
Ketamine is a tranquilizer used to induce loss of consciousness and relieve pain and can 
be linked to a gradual reduction in an individual’s driving abilities [30].  PCP can cause 
severe driving imparities and has been discovered in drugged driving cases [31].  
Synthetic cannabinoids contain receptor agonists that imitate the effects of cannabinoids 
and can therefore cause impairing driving effects comparable to cannabis.  Similarly 
these drugs may induce drowsiness, distraction, and weakened fine motor skills [32].        
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3. RESULTS & DISCUSSION  
This study summarizes the results of the toxicological findings in DWI cases 
obtained from the NYC OCME FTL to estimate alcohol and drug-involved driving 
prevalence.  It is important to note that this is a prevalence study and not a study that 
reports the risks associated with drugged-driving.  Since many drugs may be detected 
long after its impairing effects are gone, the focus of this study was to merely convey the 
use of particular drugs in the driving population.  Analyses of blood, serum and urine 
samples identified over 100 drugs and metabolites (Table 1) in the study.  To evaluate the 
results of the toxicological findings, the drugs were grouped into six classes:  
antidepressants, cannabinoids, narcotic analgesics, sedatives, stimulants and other.     
 
3.1 Driver Drug Use Prevalence Based on Specimens Analyzed  
 The following are results of the toxicological analyses for all of the drugs 
specified in the methods section of this paper.  If a driver tested positive for one or more 
of the drugs tested in blood, serum or urine, the individual was classified as drug-
positive.  In Table 2, alcohol was excluded as a drug and not counted as drug-positive if 
present.  Among the total daytime and nighttime drivers, 18.6% and 60.3%, respectively, 
were positive for alcohol whether alone or in combination with a drug.  Approximately 
76.0% of the 167 daytime drivers in the study were drug-positive.  About 35.2% of the 
443 nighttime drivers were drug-positive.   
The prevalence of drug-positive drivers significantly differed by 40.8% between 
daytime and nighttime.  Seeing as the bulk of alcohol-related incidences occur at night 
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[13], the data in the study support this and is observed with the majority of drug-positive 
data being identified during the daytime.       
  
Table 2.  Drug Prevalence by Time of Day.  Drug-positive excluded the presence of 
alcohol. 
 
 2015 
(%) 
2016 
(%) 
2017 
(%) 
Total % 
Drug-Positive 
Daytime 62.2 73.7 73.8 76.0 
Nighttime 25.9 38.5 38.6 35.2 
 
 
3.2 Driver Alcohol and Drug Use Prevalence by Drug Class  
 The following are results of the toxicological analyses for drug use by class of 
drug.  The classes of drugs tested for were alcohol, antidepressants, cannabinoids, 
narcotic analgesics, sedatives, stimulants and other (see Table 1).   
In comparing prevalence of drug classes by year, the percent of cases tested 
positive for cannabinoids, narcotic analgesics and stimulants changed significantly from 
2015 to 2017 (Table 3).  The prevalence rate of cannabinoids increased significantly in 
2017 (χ2 = 9.6, p= .008) to 43.0% from 32.5% the previous year and 29.3% in 2015.  This 
was contrary to the National Forensic Laboratory Information System’s (NFLIS) 2016 
annual report, comprised of State and local forensic laboratory seized drug results in the 
US, which reported a decrease in cannabis/THC through 2016 [33].  The prevalence of 
sedatives increased from 19.5% to 35.5% from 2015 to 2016.  According to the NFLIS 
2016 annual report, there was an increase in alprazolam (in the sedative drug class) and 
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fentanyl (in the narcotic analgesic drug class) cases.  Specifically in the Northeast region, 
alprazolam increased through 2016.  Alprazolam comprised 60% of the sedatives and 
depressants reported in 2016 [33].           
The narcotic analgesics prevalence rate increased significantly in 2016 (χ2 = 13.5, 
p= .001) to 28.5% from 13.4% in the previous year. This significant increase in narcotic 
analgesics observed in 2016 coincides with the opioid epidemic in the nation.  The use 
and abuse of opioids continue to be a serious public health problem.  Opioids are highly 
addictive and dangerous when misused.  In 2015, opioids were identified in 63% of all 
drug overdose cases in the US and had increased 16% in the opioid death rate from 2014.  
In addition to methadone, synthetic opioids associated with the death rate, including 
fentanyl, increased by 72% [34].  The findings from that report agree with the 2016 
annual NFLIS report, which states fentanyl dramatically increased starting in 2014 in the 
Northeast region.  Fentanyl along with oxycodone and hydrocodone accounted for 66% 
of narcotic analgesics [33].   
Comparison of stimulants by year showed a significant increase in 2017 (χ2 = 7.6, 
p= .023), 28.1% versus 19.0% (2016) versus 18.3% (2015).  The remaining drug classes 
did not change significantly. Anti-depressants were infrequently encountered in the study 
population.  Overall, alcohol was the most commonly detected drug in 2015 (43.3%) and 
2016 (36.0%); however, it was surpassed by cannabinoids in 2017 (43.0%).   
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 In comparing drug classes by gender and race/ethnicity, gender did not show a 
significantly different prevalence rate for any of the classes (Table 4).  However, 
significant differences were observed by race/ethnicity for the following drug classes:  
alcohol, sedatives and stimulants.  African American drivers were significantly more 
likely to test positive for alcohol than the other races (χ2 = 17.6, p= .007) with 47.1% 
prevalence versus 28.3%, 40.9% and 34.3% for White, Hispanic and Asian/Pacific 
Islander, respectively.  White drivers were significantly more likely to test positive for 
sedatives than other races (χ2 = 40.8, p= .000).  White drivers showed a prevalence rate of 
43.4% in the sedative drug class compared to 29.3%, 12.5% and 28.6% for Hispanics, 
African Americans and Asian/Pacific Islander, respectively.  White drivers were also 
significantly more likely to test positive for stimulants (χ2 = 20.2, p= .003) with a 32.0% 
prevalence rate compared to 20.7%, 15.4% and 20.0% for Hispanics, African Americans 
and Asian/Pacific Islander, respectively.                   
Table 3. Drug Classes Distribution by Year.   
 
Drug Class 2015 (%) 
2016 
(%) 
2017 
(%) 
Alcohol 43.3 36.0 35.7 
Antidepressants 3.0 2.0 4.0 
Cannabinoids* 29.3 32.5 43.0 
Narcotic Analgesics* 13.4 28.5 26.9 
Sedatives 19.5 35.5 33.7 
Stimulants* 18.3 19.0 28.1 
Other 15.2 12.5 18.9 
 
* Indicates statistically significant differences (p < .05).  
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When investigating drug classes by age, the prevalence of drug-positive drivers 
was compared against the drug-negative drivers (Table 5).  The mean age of drivers who 
tested positive for cannabinoids (m=37, sd=12) was significantly higher than those who 
tested negative (m=31, sd=11), p= .00.  Drivers who tested drug positive for narcotic 
analgesics showed a significantly lower mean age (m=34, sd=12) than those who tested 
negative (m=38, sd=12), p= .00.  The mean age of drivers who tested positive for anti-
depressants (m=35, sd=12) was significantly lower than those who tested negative 
(m=42, sd=12), p= .01.   
Table 4. Drug Classes Distribution by Gender & Race/Ethnicity.   
 
Drug Class 
Gender 
(%) 
Race/Ethnicity 
(%) 
Male Female White Hispanic African American 
Asian/Pacific 
Islander 
Alcohol 36.6 46.0 28.3 40.9 47.1* 34.3 
Antidepressants 3.0 3.4 4.6 1.2 1.5 2.9 
Cannabinoids 36.0 35.6 32.4 35.4 45.6 31.4 
Narcotic 
Analgesics 25.1 16.1 38.4 22.0 9.6 5.7 
Sedatives 30.3 32.2 43.4* 29.3 12.5* 28.6 
Stimulants 21.1 31.0 32.0* 20.7 15.4 20.0 
Other 15.8 16.1 18.7 20.7 11.8 5.7* 
 
* Statistically significant differences, p < .05  
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In comparing prevalence of drug classes by borough (Table 6), there was a 
significant difference in drug use for alcohol, narcotic analgesics and other drugs.  In 
Manhattan, there was a significantly higher alcohol detection rate compared to the other 
boroughs (χ2 = 17.5, p= .004).  With the exclusion of alcohol, cannabinoids as a single 
drug were the most common, however, as a class, cannabinoids were common across 
three of the boroughs (Bronx, Brooklyn, Manhattan), tied with sedatives in Queens and 
third most common after sedatives and narcotic analgesics in Staten Island.  In Staten 
Island there was a significantly higher narcotic analgesics detection rate (χ2 = 19.0, p= 
.002) compared to the other four boroughs.  In the Bronx and Staten Island there was a 
significantly higher detection rate of “Other” drugs (χ2 = 13.5, p= .019).            
Table 5. Drug Classes Distribution by Mean Age.   
 
Drug Class Drug-Positive Drug-Negative  T-Test m†, sd‡ m†, sd‡ t§, p(( 
Alcohol 35.1, 12.2 34.7, 11.6 .4, .72 
Antidepressants 34.7, 11.9 42.0, 11.9 -2.7, .01* 
Cannabinoids 37.2, 12.0 30.9, 10.9 6.6, .00* 
Narcotic 
Analgesics 34.0, 11.8 38.0, 12.0 -3.6, .00* 
Sedatives 35.2, 12.0 34.3, 11.9 .93, .35 
Stimulants 34.7, 12.1 35.9, 11.6 -1.1, .29 
Other 34.6, 11.9 36.5, 12.5 -1.4, .16 
 
* Statistically significant differences, p < .05  
† m = mean 
‡ sd= standard deviation  
§ t-test 
(( p-value 
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The top five drugs and additional noteworthy drugs were identified and listed per 
borough (Figure 3).  The top five were mostly similar in all five boroughs and varied 
based on the order it appeared in the list.  In comparing the top five individual drugs 
identified by borough, cannabinoids were the most common drug compared to other 
drugs across all of the boroughs.  Alprazolam and cocaine (identified by its metabolite, 
benzoylecgonine, 98% of the time) were the next most frequently encountered drugs 
alternating as the top two and three drugs identified in the following four boroughs:  
Manhattan, Queens, the Bronx, Staten Island.  Levamisole, which is a common cutting 
agent in cocaine, originally appeared as the fifth most common drug in Queens.  Positive 
levamisole detections coexisted with benzoylecgonine and were therefore excluded from 
the list.  PCP (“angel dust”) was identified in the top five for Manhattan, the Bronx and 
Staten Island.  Noteworthy drugs in Manhattan included MDMA (“Molly”/“ecstasy”).  
The national MDMA reports depicted a gradual increase in the drug through 2016 [33].  
Table 6.  Drug Classes Distribution by Borough.   
 
Drug Class Bronx (%) 
Brooklyn 
%) 
Manhattan 
(%) 
Queens 
(%) 
Staten 
Island  
(%) 
Alcohol 40.7 32.6 51.9* 39.2 28.1 
Antidepressants 0.0 5.1 3.8 3.1 4.1 
Cannabinoids 40.0 37.1 34.2 36.9 30.6 
Narcotic Analgesics 18.6 26.8 12.7 23.3 35.5* 
Sedatives 27.1 25.4 24.1 36.9 38.0 
Stimulants 20.0 20.3 24.1 27.7 22.3 
Other 22.9* 10.9 8.9 13.1 20.7* 
 
* Statistically significant differences, p < .05  
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The other three boroughs were noteworthy in synthetic opioid analgesics (e.g., fentanyl 
and U-47700).  Ketamine has not only become a drug of abuse, but also a recreational 
drug that is noteworthy in Queens.  
 The most prevalent drugs in the NFLIS 2016 annual report for the nation was 
cannabinoids, trailed by methamphetamine, cocaine, heroin and alprazolam [33].  
Specifically in the Northeast region, the top five frequently identified drugs were 
cannabinoids, heroin, cocaine, fentanyl and oxycodone.  As observed by borough below, 
cannabinoids coincides as the most frequently identified drug.  While heroin was not in 
the top five drugs for Manhattan and the Bronx, the presence of morphine in the other 
three boroughs may be indicative of heroin, since it is a metabolite for that drug.  The 
metabolite of cocaine, benzoylecgonine, is present as a top five drug in all the boroughs.  
Fentanyl was frequently identified in the Northeast, and was present as a top five drug in 
Brooklyn and Queens, while noteworthy in the Bronx and Staten Island.     
PCP may not have been in the top five drugs identified in the NFLIS report, 
however, it was part of the twenty-five most frequently identified drugs [33].  The report 
indicated that between January 1, 2016 and December 31, 2016, the highest percentage of 
PCP was found in the Northeast region of the country, which coincides with our findings 
in this study.  While historically PCP has been used as a surgical anesthetic and later as 
an animal tranquilizer, today, it is most commonly found laced with other drugs.  In 
addition to snorting the drug and taking tablets, users are now smoking marijuana laced 
with PCP [35].  PCP is not generally a top five drug identified in toxicology laboratories 
as it pertains to HPFT cases; however, when studying the drug with respect to its 
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coexistence with cannabinoids, 46.3% of the drivers who tested positive for PCP, also 
preliminarily tested positive for the use of cannabinoids.  The presence of PCP as a top 
five drug in three of the five boroughs in this study may bring awareness to this 
extremely dangerous drug on the streets of NYC. There’s no telling whether the 
powdered form of PCP is being applied to leafy substances such as marijuana or if 
cannabinoids are being dipped into the liquid form of PCP.  
 Amphetamines, which are broadly categorized as phenethylamines and grouped in 
this study under stimulants, were observed as a top five drug in Manhattan.  These drugs 
are often linked with deadly side effects and violent behavior.  According to the NFLIS 
2016 report, methamphetamine accounted for approximately 21% of the phenethylamines 
in the Northeast region as reported by the State and local forensic laboratories [33].  The 
use of drugs such as amphetamines, benzodiazepines, z-hypnotics, cannabinoids, cocaine 
and opioids suggestively increase the risk of fatal-, injury-, and/or property damage 
associated with road traffic crashes [8, 36-37].  The benzodiazepine drug group, which 
falls in the sedative drug class, has been shown to impair driving skills on a similar level 
to alcohol impaired driving.  Subjects using benzodiazepines are twice as likely to be 
involved in a crash [38].     
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Figure 3. Map of Five Boroughs of New York City and Top Five Drugs Prevalent.  
(1) Manhattan, (2) Brooklyn, (3) Queens, (4) Bronx and (5) Staten Island.  
 
* Noteworthy drugs in addition to the top five. 
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3.3 Driver Alcohol and Cannabinoid Use Prevalence by Year and Day of the Week  
 The following are results of the toxicological analyses for the presence of alcohol 
and cannabinoids over time, by day of week and in combination.   
In comparing prevalence of alcohol and cannabinoids by year, the percent of 
cases tested positive for cannabinoids changed significantly from 2015 to 2017 (Table 7).  
The prevalence rate of cannabinoids increased over time, more specifically, significantly 
increased in 2017 (χ2 = 9.6, p= .008) to 43.0% from 32.5% the previous year and 29.3% in 
2015. Although comparison of alcohol by year showed gradual decrease over time, the 
differences were not statistically significant between the proportions of alcohol positive 
cases from 2015 to 2017.  The results of alcohol in 2016 and 2017 show similar relative 
patterns of prevalence estimates.      
 Numerous on-road studies have been conducted on marijuana impaired driving, 
investigating the effects of cannabinoids on driving performance.  The results of these 
studies indicate that marijuana use can lead to a reduction in driving abilities.  Drivers 
with high doses of marijuana use had a higher risk of striking cones during a driving task 
(five times more likely) than individuals not affected by marijuana [39-42].  
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Table 8 provides a further look at the issue of alcohol and cannabinoids identified 
in combination with one another and reveals that drivers who tested positive for 
cannabinoids had a significantly lower incidence of 40.5% for testing positive for alcohol 
than those who tested negative for cannabinoids having an incidence of 53.2% (χ2 = 11.2, 
p= .001).  The use of drugs in combination with alcohol has been shown to have more 
impairing effects than drugs alone.  A study found that approximately one-half of the 
incidences where drivers were found positive for marijuana had higher BACs than those 
positive for drugs alone and those drivers negative for the combination of alcohol and 
drugs [6].  Contrary to this, a statistically significant negative association was found 
between cannabinoid-positive and alcohol-positive drivers.  The percentage of drivers 
with a BAC greater than .08 g/dL was significantly lower among cannabinoid-positive 
drivers than those who tested negative for cannabinoids.  Although the results indicated a 
negative association between alcohol and cannabinoids, the combination of the two drugs 
is known to critically impair performance [43].   
 
Table 7. Alcohol & Cannabinoids Distribution by Year.   
 
Drug Class 2015 (%) 
2016 
(%) 
2017 
(%) 
Alcohol 43.3 36.0 35.7 
Cannabinoids* 29.3 32.5 43.0 
 
* Statistically significant differences, p < .05  
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As indicated in Table 9, the prevalence of alcohol positives by day of the week 
(53%) was significantly higher among Sunday drivers (χ2 = 25.2, p= .001).  When 
examining cannabinoid prevalence by day of the week, 54% of the drivers significantly 
tested positive for Tuesday (χ2 = 18.0, p= .012).     
 
3.4 Correlation Analyses between Drug Classes and Demographics  
 The following are results of the correlation study between the positive alcohol 
and/or drug cases among each drug class and with the demographic variables in the 
study.  In the first part of the study, the drug classes were analyzed for their correlation to 
each other.  As shown in Table 10, there were several mild to moderate correlations 
among the drug categories.  The drug classes were categorized 1 through 7 in the 
Table 8. Drug Prevalence by Alcohol and/or Cannabinoids.   
 
  Cannabinoids 
  Positive (%) Negative (%) 
Alcohol Positive (%) 40.5* 53.2 Negative (%) 59.5 46.8 
 
* Statistically significant differences, p < .05  
 
Table 9. Alcohol & Cannabinoids Distribution by Day of the Week (Percentages 
Calculated by Column).   
 
Drug Class M T W Th F Sa Su Total 
Alcohol 33 22 25 38 38 43 53* 38 
Cannabinoids 38 54* 4 32 22 36 36 36 
 
* Statistically significant differences, p < .05  
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following order:  alcohol, cannabinoids, narcotic analgesics, antidepressants, sedatives, 
stimulants and other.  Although there were no strong correlations between drug classes, 
sedatives were associated (according to significant correlations) with most other drugs 
(correlated to 6 out of 6 categories).  In particular, sedatives had a medium strength 
correlation with narcotic analgesics, which may be cognizant of the use of sedatives, 
specifically benzodiazepines, in place of opioids by drivers.  The different shades of gray 
in the table correspond to the correlation strengths depicted below and are further detailed 
in the Appendix A, Table A.   
 
In the second part of the correlation study, the drug classes were analyzed for 
their correlation to the demographic characteristics of the drivers, day of the week and 
location (borough).  As shown in Table 11, the associations between drug categories and 
the influencing variables are not terribly strong. There were several mild to moderate 
Table 10. Correlation Strength between Drug Classes  
 
Category 
No. Drug Class 
No. of 
Correlations 
to Other 
Drugs 
Strong Medium  (.2-.4)’ 
Small 
(.1-.2) 
1 Alcohol* 5 of 6 - 3, 7 2, 5, 6 
2 Cannabinoids 3 of 6 - - 1, 3, 5 
3 Narcotic 
Analgesics 4 of 6 - 1, 5 2, 6 
4 Antidepressants 2 of 6 - - 5, 6 
5 Sedatives 6 of 6 - 3, 6 1, 2, 4, 7 
6 Stimulants 5 of 6 - 5, 7 1, 3, 4 
7 Other 3 of 6 - 1, 6 5 
 
* Alcohol = .08 g/dL BAC or higher 
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correlations among the independent variable categories and drug categories.  The drug 
classes were categorized 1 through 7 in the following order:  alcohol, cannabinoids, 
narcotic analgesics, antidepressants, sedatives, stimulants and other.  The different shades 
of gray in the table correspond to the correlation strengths depicted below and are further 
detailed in the Appendix A, Table B.   
   The correlation between age and drug categories revealed a medium negative 
strength with cannabinoids (2), indicating that a younger age group is associated with 
cannabinoid use in drivers.  Age also had a small positive association with narcotic 
analgesics (3) and antidepressants (4), indicating that those who use them are slightly 
older.  Gender did not have a significant association with any of the drug categories.   
The association between race/ethnicity and drug categories revealed a small 
negative strength with narcotic analgesics in Asian/Pacific Islanders and African 
Americans, indicating drivers in those two races are less likely to use opioids.  African 
American drivers were the least likely to use sedatives (5), as shown by a medium 
negative association in the study.  White drivers were the most likely to use sedatives and 
narcotic analgesics, both indicated by medium positive associations.  There were only 
small associations whether negative or positive between the day of the week and drug 
categories.  Similarly, only small associations were present between location (borough) 
and drug categories.      
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Table 11. Correlation Strength between Drug Classes, Demographics, Day of the 
Week and Location (Borough)  
 
Category 
No. 
Independent Variable 
Categories Strong Medium  Small 
1 Age - 2 3, 4 
2 Gender - - - 
3 Asian/Pacific Islander - - 3 
4 African American - 5 1, 2, 3, 6 
5 Hispanic - - - 
6 White - 3, 5 1, 6 
7 Monday - - - 
8 Tuesday - - 1, 2, 5 
9 Wednesday - - 1, 6 
10 Thursday - - 5 
11 Friday - - 2 
12 Saturday - - - 
13 Sunday - - 1 
14 Bronx - - 4 
15 Brooklyn - - - 
16 Manhattan - - 1, 3 
17 Queens - - - 
18 Staten Island - - 1, 3 
 
 
3.5 Logistic Regression Model for each Drug Class 
 Logistic regression analysis was employed to evaluate the influence of 
demographic characteristics and location/borough on drug use in drivers.  The predictor 
variables were driver’s age, race, gender and location/borough (Appendix A, Table C).  
The demographic variables provided a small amount of predictive power using logistic 
regression to build a model (as expected from the low correlations indicated in the section 
above).  A binary logistic regression based predictive model was used to create the lift 
chart seen in Table 11, which measured the effectiveness of the model-based selection 
compared to a random selection (null).  The lift value indicated how much the model 
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differed from the null instance.  For alcohol, there was a 26.6% increase by using the 
predictive model than the random null instance.  By using the model for alcohol we were 
able to better predict that a driver influenced by the independent variables considered in 
the regression would have used alcohol (having a .01 g/dL BAC or higher).  
Cannabinoids resulted in an 8.3% better predictive result by using the model compared to 
the random null instance.  By using the model, we were able to better predict that a driver 
influenced by the independent variables considered in the regression would have used 
cannabinoids.  For the remaining drugs, the model did not prove to be valuable since it 
predicted very similar values to the null.           
Omnibus tests of the model coefficients were used to check whether the new 
model is an improvement over the baseline model (null).  The results included chi-square 
tests to determine if there was a significant difference between the log-likelihood of the 
baseline model and the new LR model.  Although all of the models were significant, it 
was because of the large sample size and not because of great predictive value.   
Table 12. Predictive “Lift” from the Model using Independent Variables.    
 
Drug Class of 
Interest 
Null 
(%) 
Model 
(%) 
Lift 
(%) 
Alcohol* 51.5 65.2 126.6 
Cannabinoids 64.1 69.4 108.3 
Narcotic Analgesics 76.1 75.8 99.6 
Sedatives 69.4 70.9 102.1 
Stimulants 77.5 77.8 100.4 
Other 84.2 84.0 99.8 
 
* Alcohol = .01 g/dL BAC or higher 
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This investigation will prove useful to policymakers in terms of developing and 
implementing strategies to address the current drug epidemic in the US, specifically in 
NYC.  The data and results obtained from the study will help NYC make headway in 
decreasing the frequency with which alcohol-and drug-involved driving occurs.  It will 
also prove useful to toxicology laboratories analyzing HPFT cases to determine which 
types of drugs to incorporate in their screening of specimens submitted for DWI cases.   
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4. CONCLUSIONS 
 Overall, the toxicological findings from the samples in the study showed daytime 
drivers had a drug use prevalence rate of 76.0% and 35.2% for nighttime drivers in the 
three-year timeframe.  Daytime data was specified as 8 a.m. to 5:59 p.m. and nighttime 
data was specified from 6 p.m. to 7:59 a.m.  The daytime versus nighttime analysis 
excluded alcohol, allowing us to conclude that drugs are more prevalent among daytime 
drivers involved in DWI incidences. Drug prevalence was indicated by a single drug 
present and excluded the presence of alcohol unless measuring prevalence in the alcohol 
drug class.  Apart from alcohol, cannabinoids were the most frequently identified single 
drug in the study.  The cannabinoid use prevalence rate increased gradually over the three 
years and suggested a statistically significant negative association between cannabinoid-
positive and alcohol-positive drivers.  This indicates that cannabinoid use is more often 
found on its own in drivers versus in combination with alcohol and may present a larger 
issue than drunk driving in NYC, an important finding given the current push for 
legalization of recreational marijuana use in NYS.        
Given that no strong correlations were present among the drugs and independent 
variables studied, it can be said that drug-use patterns are challenging to predict since 
drug prevalence varies not only among the demographic factors considered in this study, 
but also across time and location.  The overall estimates in the study pertain to the group 
of road traffic cases sent to and tested by the NYC OCME FTL for alcohol and drugs 
from 2015 to 2017.  The estimates do not apply to all arrested NYC drivers or to all 
drivers on the road.  Starting in 2018, the FTL currently receives all potential drunk- and 
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drugged-driving cases from the NYPD and would make for a better estimate in future 
studies.         
 
4.1 Potential Bias & Limitations 
The data in this study includes toxicological findings from completed analyses by 
OCME FTL only.  The Liaison Unit between the NYPD crime lab and FTL may not have 
always correctly identified the drug DWI cases for testing by the FTL.  Furthermore, the 
NYPD Police Laboratory may have just tested for alcohol as requested, and if positive, 
no further drug toxicological analysis would be performed, thus overlooking any 
potential drug findings.  As a result of these possibilities, not all NYC DWI drug cases 
would have been analyzed.  However, as of 2018, all NYC DWAI cases were submitted 
to the OCME FTL of NYC and no toxicological testing (blood alcohol) is performed by 
the NYPD.   
Data collection was also limited by the completeness and quality of reporting 
obtained from the NYPD Complaint Form.  The data on the forms submitted with each 
case to the FTL are self-reported by the responding officer at the scene.  The responding 
officer does not always complete all data fields in the complaint form.  These 
inconsistencies present limitations in collecting variable information used in the study 
such as vehicle type, which was excluded from the study due to too many unknowns.    
Potential bias seen in this study was the selection of the study population.  The 
population that was chosen for this study did not represent the population as a whole.  A 
case-control study that compares the percent of drugs detected in crash-involved drivers 
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with the percent in non-crash involved drivers at the times and places of the crashes 
would depict better, shrewd estimates of alcohol and drug prevalence while operating a 
motor vehicle. In addition, while the study produced notable statistics regarding the data 
collected, these numbers provide only a rough idea of the magnitude of the drug-crash 
risk associated with drugged driving.  Drug prevalence may have been under-represented 
if the entire drug (parent/metabolites) was metabolized prior to toxicological initial 
screening.  On the other hand, toxicological findings may have been misrepresented in 
the cases where only urine specimen was available for testing. Since urine offers a 
somewhat longer window of detection for substances, testing of urine does not 
necessarily mean that the individual was under the influence of said drug at the time of 
the arrest, it means that they had used it as some point and their body has eliminated it.  
Blood testing (from a blood draw time closest to the time of occurrence) is always more 
accurate as to what is in the individual’s system at the time of arrest/crash.   
Moreover, the legality and use of the drugs by drivers are not easily 
distinguishable.  It is difficult to discern between legal and illegal drugs and whether they 
are being used for medical or nonmedical purposes.  A larger sample size in the 
correlation study may have resulted in more significant findings between the presence of 
drugs and crash risk.   
 
4.2 Future Directions  
In the future, obtaining the Intoxicated Driving Testing Unit’s (IDTU) Arresting 
Officers Report and Intoxicated Driver Examination Sheet would be useful to compare 
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the breath alcohol concentration (BrAC) results to the toxicological analysis of the BAC 
measured by HS-GC from the OCME FTL findings.  This comparison may be used to 
identify the accuracy with which the values recorded from the Intoxilyzer BrAC by the 
IDTU technician are consistent with the OCME findings.  Additionally, this would be a 
measure of accuracy in rightful arrests by officers per Intoxilyzer results. It would also be 
very beneficial to compare the toxicological findings from the FTL to the Intoxicated 
Driver Examination Sheet or a Standardized Field Sobriety Test (SFST) performed by 
Drug Recognition Expert (DRE) when available. Further, it would be interesting to 
compare the physical and behavioral findings per the DRE to toxicological findings.      
 In addition, obtaining the New York State Prescription Monitoring Program (NYS 
PMP) data to compare opioid data from the cases to the most frequently prescribed drugs 
in the city would be beneficial.  The PMP provides access to recent controlled substance 
prescription history of an individual and helps practitioners monitor and evaluate an 
individual’s treatment.  The PMP was implemented to control “Doctor Shoppers” and 
contain the opioid epidemic issues.  It would be beneficial to investigate how the data 
from this study correlates to the amount of prescription drugs in the general population. 
The new Internet System for Tracking Over-Prescribing (I-STOP) law was implemented 
in March 27, 2016. New York state prescribers have fully transitioned to electronic 
prescribing and would definitely be an interesting component of research going forward.  
The toxicological findings in this study represent the alcohol and drug prevalence 
among the drivers.  Future studies should be done to determine the crash risk associated 
with the effect of the prevalent drugs in this study.  
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APPENDIX A:  [ADDITIONAL TABLES] 
Table A.  Drug Correlation by Drug Class 
Drug Class 
Category No.  1 2 3 4 5 6 7 
  NPCat-
Ethanol08 
NPCat-
Cannabanoids 
NPCatNarcotic-
AllOpioids 
NPCatAnti-
Depresent 
NPCat-
Sedatives 
NPCat-
Stimulants 
NPCat-
Other 
NPCatEthanol08 
Pearson 
Correlation 
1 -.135** -.294** -0.023 -.188** -.163** -.219** 
Sig. (2- ailed)   0.001 0.000 0.568 0.000 0.000 0.000 
N 613 613 613 613 613 613 613 
NPCatCannabanoids 
Pearson 
Correlation 
-.135** 1 -.107** -0.075 .140** 0.069 0.048 
Sig. (2-tailed) 0.001   0.008 0.064 0.001 0.088 0.232 
N 613 613 613 613 613 613 613 
NPCatNarcoticAllOpioids 
Pearson 
Correlation 
-.294** -.107** 1 .099* .270** .166** 0.030 
Sig. (2-tailed) 0.000 0.008   0.014 0.000 0.000 0.452 
N 613 613 613 613 613 613 613 
NPCatAntiDepresent 
Pearson 
Correlation 
-0.023 -0.075 .099* 1 .168** .106** 0.051 
Sig. (2-tailed) 0.568 0.064 0.014   0.000 0.008 0.204 
N 613 613 613 613 613 613 613 
NPCatSedatives 
Pearson 
Correlation 
-.188** .140** .270** .168** 1 .254** .150** 
Sig. (2-tailed) 0.000 0.001 0.000 0.000   0 0.000 
N 613 613 613 613 613 613 613 
NPCatStimulants 
Pearson 
Correlation 
-.163** 0.069 .166** .106** .254** 1 .280** 
Sig. (2-tailed) 0.000 0.088 0.000 0.008 0   0.000 
N 613 613 613 613 613 613 613 
NPCatOther 
Pearson 
Correlation 
-.219** 0.048 0.030 0.051 .150** .280** 1 
Sig. (2-tailed) 0.000 0.232 0.452 0.204 0.000 0.000   
N 613 613 613 613 613 613 613 
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Table B.  Drug Correlation by Drug Class 
 
    Drug Category 
No.  
1 2 3 4 5 6 7 
No.  
Independent 
Variable 
Categories 
  NPCat-
Ethanol08 
NPCat-
Cannabanoids 
NPCatNarcotic-
AllOpioids 
NPCat-
AntiDepressant 
NPCat-
Sedatives 
NPCat-
Stimulants 
NPCat-
Other 
1 Age 
Pearson Correlation -0.015 -.252** .146** .105** -0.038 0.043 0.058 
Sig. (2-tailed) 0.716 0.000 0.000 0.009 0.351 0.287 0.155 
N 612 612 612 612 612 612 612 
2 NSex 
Pearson Correlation 0.025 -0.024 -0.068 0.000 -0.009 0.042 -0.011 
Sig. (2-tailed) 0.542 0.561 0.093 0.991 0.822 0.298 0.792 
N 613 613 613 613 613 613 613 
3 Race2Asian 
Pearson Correlation -0.018 -0.023 -.105** -0.003 -0.010 -0.015 -0.068 
Sig. (2-tailed) 0.655 0.572 0.010 0.932 0.798 0.715 0.092 
N 613 613 613 613 613 613 613 
4 Race3Black 
Pearson Correlation .101* .108** -.179** -0.050 -.209** -0.109 -0.059 
Sig. (2-tailed) 0.012 0.007 0.000 0.215 0.000 0.007 0.142 
N 613 613 613 613 613 613 613 
5 Race4Hispanic 
Pearson Correlation 0.059 -0.009 -0.035 -0.018 -0.038 -0.040 0.067 
Sig. (2-tailed) 0.146 0.829 0.384 0.655 0.348 0.319 0.097 
N 613 613 613 613 613 613 613 
6 Race5White 
Pearson Correlation -.147** -0.054 .254** 0.063 .208** .169** 0.059 
Sig. (2-tailed) 0.000 0.182 0.000 0.119 0.000 0.000 0.143 
N 613 613 613 613 613 613 613 
7 DayMonday 
Pearson Correlation -0.032 0.014 0.041 -0.032 0.056 -0.036 -0.035 
Sig. (2-tailed) 0.424 0.722 0.316 0.433 0.169 0.373 0.384 
N 613 613 613 613 613 613 613 
8 DayTuesday 
Pearson Correlation -.116** .129** .081* -0.031 .152** 0.017 0.054 
Sig. (2-tailed) 0.004 0.001 0.045 0.443 0.000 0.668 0.182 
N 613 613 613 613 613 613 613 
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Table B. Drug Correlation by Class (Continued) 
9 DayWednesday 
Pearson Correlation -.100* 0.029 0.043 .080* 0.063 0.103 0.075 
Sig. (2-tailed) 0.013 0.467 0.291 0.049 0.121 0.010 0.063 
N 613 613 613 613 613 613 613 
10 DayThursday 
Pearson Correlation 0.000 -0.034 0.005 -0.043 -.115** 0.041 0.013 
Sig. (2-tailed) 0.993 0.397 0.896 0.292 0.004 0.315 0.740 
N 613 613 613 613 613 613 613 
11 DayFriday 
Pearson Correlation 0.004 -.120** -0.004 0.002 -0.056 -0.034 -0.011 
Sig. (2-tailed) 0.922 0.003 0.919 0.955 0.168 0.397 0.789 
N 613 613 613 613 613 613 613 
12 DaySaturday 
Pearson Correlation 0.049 0.000 -0.047 -0.015 -0.006 -0.023 -0.017 
Sig. (2-tailed) 0.226 0.998 0.241 0.711 0.878 0.566 0.670 
N 613 613 613 613 613 613 613 
13 DaySunday 
Pearson Correlation .146** 0.001 -.080* 0.035 -0.062 -0.047 -0.069 
Sig. (2-tailed) 0.000 0.985 0.047 0.381 0.127 0.247 0.086 
N 613 613 613 613 613 613 613 
14 Bronx1 
Pearson Correlation 0.032 0.047 -0.067 -.097* -0.040 -0.033 .105** 
Sig. (2-tailed) 0.427 0.249 0.097 0.016 0.326 0.419 0.009 
N 613 613 613 613 613 613 613 
15 Brooklyn2 
Pearson Correlation -0.058 0.012 0.038 0.061 -0.060 -0.029 -0.073 
Sig. (2-tailed) 0.150 0.767 0.349 0.129 0.136 0.478 0.070 
N 613 613 613 613 613 613 613 
16 Manhattan 
Pearson Correlation .111** -0.014 -.101* 0.015 -0.054 0.014 -0.073 
Sig. (2-tailed) 0.006 0.734 0.013 0.702 0.182 0.726 0.069 
N 613 613 613 613 613 613 613 
17 Queens4 
Pearson Correlation 0.015 0.011 -0.009 -0.001 0.072 0.064 -0.039 
Sig. (2-tailed) 0.714 0.782 0.824 0.987 0.074 0.112 0.334 
N 613 613 613 613 613 613 613 
18 StatenIsl5 
Pearson Correlation -.100* -0.055 .136** 0.030 .081* -0.002 0.066 
Sig. (2-tailed) 0.014 0.175 0.001 0.465 0.045 0.954 0.104 
N 613 613 613 613 613 613 613 
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Table C. Logistic Regression Variables – Dependent/Independent 
LR VARIABLES 
Dependent Independent Variables 
Alcohol† Age 
Cannabinoids Gender 
NPCatNarcoticAllOpioids Race 
NPCatSedatives Location (borough) 
NPCatStimulants Day of the Week 
NPCatOther  
* Dependent Variables were created for the drug classes, NP = negative or positive for at 
least one drug in that drug category (Cat)  
† Alcohol = .01 BAC or higher  
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Table D. Logistic Regression Model for each Drug Class:  Baseline Prediction versus LR Model Prediction   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model 1: DV = Cannabinoids, IVs = Race, Gender, Age, and Location (Borough) 
      Predicted           Predicted   
Step 0: 
Baseline 
Prediction     .00 1.00 
% 
Correct   
Step 1: Prediction 
Based on the Model 
    .00 1.00 
% 
Correct 
Observed 
Not .00 392 0 100.0   
Observed 
Not .00 347 45 88.5 
Cannabinoids 1.00 220 0 0.0   Cannabinoids 1.00 142 78 35.5 
Overall 
Percentage 
      64.1   Overall 
Percentage 
      69.4 
a. Constant is included in the model.         a. The cut value is .500         
b. The cut value is .500                       
                          
Model 2: DV = Alcohol (.01+), IVs = Race, Gender, Age, and Location (Borough) 
      Predicted           Predicted   
Step 0: 
Baseline 
Prediction     .00 1.00 
% 
Correct   
Step 1: Prediction 
Based on the Model 
    .00 1.00 
% 
Correct 
Observed 
Not .00 315 0 100.0   
Observed 
Not .00 224 91 71.1 
Alcohol 1.00 297 0 0.0   Alcohol 1.00 122 175 58.9 
Overall 
Percentage 
      51.5   Overall 
Percentage 
      65.2 
              a. The cut value is .500         
  
Model 3: DV = Narcotics, IVs = Race, Gender, Age, and Location (Borough) 
      Predicted           Predicted   
Step 0: 
Baseline 
Prediction     .00 1.00 
% 
Correct   
Step 1: Prediction 
Based on the Model 
    .00 1.00 
% 
Correct 
Observed 
Not .00 466 0 100.0   
Observed 
Not .00 448 18 96.1 
Narcotics 1.00 146 0 0.0     1.00 130 16 11.0 
Overall 
Percentage 
      76.1   Overall 
Percentage 
      75.8 
a. Constant is included in the model.         a. The cut value is .500         
b. The cut value is .500                       
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 Model 4: DV = Sedatives, IVs = Race, Gender, Age, and Location (Borough) 
  
NPCat-
Sedatives   Predicted       
NPCat-
Sedatives   Predicted   
Step 0: 
Baseline 
Prediction     .00 1.00 
% 
Correct   
Step 1: Prediction 
Based on the Model 
    .00 1.00 
% 
Correct 
Observed 
Not .00 425 0 100.0   
Observed 
Not .00 386 39 90.8 
Sedatives 1.00 187 0 0.0   Sedatives 1.00 139 48 25.7 
Overall 
Percentage 
      69.4   Overall 
Percentage 
      70.9 
a. Constant is included in the model.         a. The cut value is .500         
b. The cut value is .500                      
Model 5: DV = Stimulants, IVs = Race, Gender, Age, and Location (Borough) 
  
NPCat-
Stimulants   Predicted       
NPCat-
Stimulants   Predicted   
Step 0: 
Baseline 
Prediction     .00 1.00 
% 
Correct   
Step 1: Prediction 
Based on the Model 
    .00 1.00 
% 
Correct 
Observed 
Not .00 474 0 100.0   
Observed 
Not .00 469 5 98.9 
Stimulants 1.00 138 0 0.0   Stimulants 1.00 131 7 5.1 
Overall 
Percentage 
      77.5   Overall 
Percentage 
      77.8 
a. Constant is included in the model.         a. The cut value is .500         
b. The cut value is .500                       
                          
Model 6: DV = Other, IVs = Race, Gender, Age, and Location (Borough) 
  NPCatOther   Predicted       NPCatOther   Predicted   
Step 0: 
Baseline 
Prediction     .00 1.00 
% 
Correct   
Step 1: Prediction 
Based on the Model 
    .00 1.00 
% 
Correct 
Observed 
NPCatOther .00 515 0 100.0   
Observed 
NPCatOther .00 514 1 99.8 
  1.00 97 0 0.0     1.00 97 0 0.0 
Overall 
Percentage 
      84.2   Overall 
Percentage 
      84.0 
a. Constant is included in the model.         a. The cut value is .500         
b. The cut value is .500                       
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